DGX
Quest Diagnostics Incorporated · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.9% ·
share flow -0.4% ·
net new positions -12.5%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | +1 | 108.65K | $24.71M | +1 | −2 |
| Q2 2026 | 152 | +1 | 77.45M | $16.40B | +7 | −8 |
| Q1 2026 | 156 | -1 | 76.50M | $14.98B | +4 | −6 |
| Q4 2025 | 156 | +4 | 87.42M | $15.15B | +5 | n/a |
| Q3 2025 | 16 | -1 | 54.97M | $10.47B | n/a | −2 |
| Q2 2025 | 15 | -3 | 44.54M | $8.00B | n/a | −3 |
| Q1 2025 | 15 | +2 | 17.80M | $3.01B | +3 | −1 |
| Q4 2024 | 13 | -2 | 18.37M | $2.77B | n/a | −2 |
| Q3 2024 | 14 | -1 | 12.70M | $1.97B | n/a | −1 |
| Q2 2024 | 15 | n/a | 9.75M | $1.33B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 14.25M | +0.1% | $2.72B | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 10.00M | -3.0% | $1.91B | 0.0% | ▼ Trim | 2 | SEC ↗ ×20 |
| 3 | JPMorgan Chase ✦ | 8.63M | n/a | $1.65B | 0.1% | n/c | 1 | SEC ↗ ×34 |
| 4 | T. Rowe Price ✦ | 7.01M | -2.6% | $1.34B | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 5.22M | +0.8% | $995.58M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 3.04M | +1.8% | $576.44M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 2.29M | n/a | $435.84M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 8 | Wellington Management ✦ | 1.44M | -9.8% | $274.79M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 9 | Fidelity (FMR) ✦ | 1.21M | -1.8% | $231.24M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 10 | Goldman Sachs Group ✦ | 1.06M | n/a | $202.72M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Marshall Wace ✦ | 557.15K | +171.7% | $106.18M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Citadel Advisors ✦ | 130.61K | +364.9% | $24.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 54.69K | +83.5% | $10.42M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 50.07K | +1.3% | $9.51M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 15 | Millennium Management ✦ | 10.36K | -93.3% | $1.97M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 5.65K | +49.7% | $1.08M | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $238.12M | was 0.0% |
| Fisher Asset Management | $219,962 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 41.40K shares, $8,113 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 10.00K sh · $2.43M
Officer · 16.01K sh · $3.89M
Officer · 6.24K sh · $1.52M
Officer · 430 sh · $105,141
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology